logo-loader
viewFrontier IP Group PLC

Frontier IP’s Cambridge Raman Imaging Limited secures €140,000 grant to accelerate development of scanning microscope

CRIL is developing a microscope which uses graphene to modulate ultra-short pulses of light to diagnose and track cancer tumours

Frontier IP Group PLC - Frontier IP’s Cambridge Raman Imaging secures €140,000 grant to accelerate development of scanning microscope

Frontier IP Group PLC’s (LON:FIPP) portfolio firm, Cambridge Raman Imaging Limited (CRIL), has been awarded €140,000 (£116,380) in EU funding to accelerate development of its graphene-enabled scanning microscope.

CRIL, which was spun out from the University of Cambridge and Italian university Politecnico di Milano in 2018, is developing a microscope which uses graphene to modulate ultra-short pulses of light to diagnose and track cancer tumours.

READ: Frontier IP ups stake in AI logistics firm Celerum

The technology will target real-time digital images of fresh tissue samples to show the extent of tumours, their response to drug treatments and to allow surgeons to see if a cancer has been completely removed.

Frontier, which owns 33.3% of the firm, said CRIL’s technology will be compact enough to be used in operating theatres, reducing the time needed for analysis which currently requires samples to be extracted from a patient and then taken to a lab.

Potential future applications include scanning bodily fluids for pathogens and tumour cells, as well as in imaging semiconductors or proteins.

The grant is funded by the EU’s graphene flagship, an initiative to help develop uses for graphene in society from academic research.

"Cambridge Raman Imaging is our first spin out to develop a graphene-based technology. Although the first applications are in healthcare, we believe there could be broader applications in other industries”, said Frontier’s chief executive Neil Crabb.

“We're delighted the EU Graphene Flagship recognises the potential of the technology with the grant award to accelerate its development", he added.

Frontier IP’s shares were steady at 65.5p in early deals on Monday.

Quick facts: Frontier IP Group PLC

Price: 54.5 GBX

AIM:FIPP
Market: AIM
Market Cap: £27.62 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Frontier IP Group PLC named herein, including the promotion by the Company of Frontier IP Group PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Frontier IP's The Vaccine Group to begin animal coronavirus vaccine trials...

Frontier IP Group PLC's (LON:FIPP) Neil Crabb tells Proactive London's  Andrew Scott its portfolio company The Vaccine Group is to 'imminently' start trials of its coronavirus vaccine in animals. Crabb says the idea is to develop an animal inoculation that would prevent the spread of...

1 week, 5 days ago

2 min read